11 results about "FGF21" patented technology

This invention relates to the field of cosmetics, and more particularly to active oligopeptides and their application in the preparation of anti-aging products. This invention provides an active oligopeptide with anti-aging activity, the amino acid sequence of which is shown in SEQ ID NO:1 and / or SEQ ID NO:4. This invention also provides an active oligopeptide (β1 and β1c) designed based on computational structural biology, targeting the β-Klotho FGF19 / / FGF21 and receptor-binding arm (RBA) region, and optimized for physicochemical properties, for use in skin anti-aging.

The application provides a curcumin composition-FGF21 functional protein co-assembly microparticle applied to liver diseases and a preparation method thereof, and comprises the following steps: extracting turmeric by dynamic warm soaking, obtaining turmeric filtrate after centrifugation, concentration and microfiltration; preparing high-purity curcumin composition through PS-NVP specific purification and 80% ethanol gradient elution; and preparing Curs-FGF21 co-assembly microparticles through oil-water phase assembly and centrifugation by taking a polymer as a carrier, compounding the curcumin composition with FGF21 protein. The microparticle can improve drug stability and bioavailability, realizes long-acting slow release, can regulate liver cell lipid metabolism, reduce liver lipid accumulation and inflammation, significantly improves liver damage and liver fibrosis, and has outstanding liver protection and repair effects. The process is stable and controllable, has outstanding innovation, and provides a brand-new candidate preparation research and development idea and technical scheme for the prevention and treatment of metabolic liver diseases.

The present application discloses the use of FGF21 / GLP-1 fusion proteins in the preparation of a medicament for preventing and / or treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia. The FGF21 / GLP-1 fusion proteins of the present application are effective in treating at least one of type 2 diabetes, obesity, steatohepatitis, and triglyceridemia, and in particular, can reduce at least one of HbA1c, blood glucose, body weight, liver fat content, ALT, AST, glutamyl transpeptidase, triglyceride, total cholesterol, low-density lipoprotein cholesterol, or increase at least one of adiponectin, insulin sensitivity, and beta-cell function in the subject.

According to various aspects of this disclosure, the present disclosure relates to a method for treating or reducing pulmonary inflammation and / or pulmonary fibrosis in a subject in need thereof comprising intramuscularly administering to the subject a recombinant adeno-associated virus (rAAV) vector. In some aspects, the rAAV vector comprises a vector genome and an AAV capsid (e.g., an AAV1 serotype). In some aspects, the vector genome comprises AAV inverted terminal repeats (ITRs) flanking an expression construct comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or functional fragment thereof operably linked to a ubiquitous promoter.

The invention relates to a viral expression construct and related viral vector and nucleic acid molecule and composition and to their use wherein said construct and vector are suitable for expression in a mammal and comprise a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) to be expressed in liver, adipose tissue and / or skeletal muscle.

GLP-1-Fc-FGF21 double-target fusion protein composition and its use. The composition comprises a GLP-1-Fc-FGF21 fusion protein and a buffer solution. In the composition, by adding the buffer solution, the formation of visible particles can be effectively controlled, the stability of the GLP-1-Fc-FGF21 fusion protein can be improved, and the shelf life of the product can be extended. The composition can be used to treat and / or prevent metabolic diseases such as diabetes, dyslipidemia, obesity, and diseases associated with fatty liver.

A fusion protein having a triple activity and a use thereof are provided. More specifically, a fusion protein has a triple biological activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and epidermal growth factor 21 (FGF21). It can be used for treating type 2 diabetes (T2D), obesity, and other diseases related to glucose and lipid metabolic abnormalities.

This invention discloses a microneedle system, its preparation method, and its applications. The microneedle system includes a microneedle substrate and a microneedle tip. The microneedle substrate is a cross-linked polyvinyl alcohol hydrogel, and the microneedle tip includes the cross-linked polyvinyl alcohol hydrogel and FGF21 and GLP-1RA encapsulated within the cross-linked polyvinyl alcohol hydrogel. This invention prepares PVA with localized ROS responsiveness. tsPBA The microneedle system co-encapsulates FGF21 and GLP-1RA, enabling them to work synergistically at the wound site to improve endothelial function, promote angiogenesis, and facilitate keratinocyte migration, thereby achieving highly effective treatment of diabetic foot ulcers.

This invention relates to the field of cosmetics, and more particularly to oligopeptides and their applications. The invention provides oligopeptides with amino acid sequences as shown in SEQ ID NO:1 or SEQ ID NO:2. This invention comprises a series of oligopeptides (including β-6 and β-683) designed based on the key interface of the β-Klotho protein. Computational models predict that these oligopeptides possess excellent binding potential and retain activity even after truncation. By mimicking the function of β-Klotho, these oligopeptides act on the FGF21-FGFR signaling pathway, thereby promoting collagen synthesis, inhibiting collagen degradation, and ultimately achieving beneficial anti-aging effects on the skin.